Renascience Inc. engages in the development and commercialization of pharmaceuticals and medical devices in Japan. The company is developing RS5614, a PAI-1 inhibitor product candidate for use in the treatment of chronic myeloid leukemia, malignant melanoma, non-small cell lung cancer, cutaneous angio-sarcoma, coronavirus lung injury, and interstitial lung disease associated with systemic scleroderma; RS5441, PAI-1 inhibitor for the treatment of alopecia disease that is in Phase I clinical trials; and RS8001, a water-soluble vitamin for use in the treatment of premenstrual syndrome/premenstrual dysphoric mood disorder and menopausal disorder, which is in phase 1 clinical trials. It is also developing RS9001, a disposable ultrafine endoscope; artificial intelligence based medical solutions; and diagnostic solutions. The company was incorporated in 2000 and is headquartered in Sendai, Japan.
तुलना करने के लिए मीट्रिक्स | 4889 | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंध4889पीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | −98.3x | 1.5x | −0.4x | |
PEG अनुपात | 0.29 | 0.03 | 0.00 | |
क़ीमत/बुक | 10.5x | 2.0x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 237.9x | 2.1x | 3.2x | |
अपसाइड (विश्लेषक लक्ष्य) | - | 18.9% | 50.5% | |
उचित मूल्य अपसाइड | अनलॉक करें | −2.8% | 5.9% | अनलॉक करें |